Physical activity, sitting time, and risk of myelodysplastic syndromes, acute myeloid leukemia, and other myeloid malignancies
Menée en 1999 auprès de 109 030 personnes (âge moyen : 69,2 ans ; durée moyenne de suivi : 10 ans), cette étude analyse l'association entre l'activité physique, d'intensité modérée à intense, le temps passé en position assise et le risque de développer une tumeur myéloïde (409 cas)
Introduction : There is limited research on associations of moderate-to-vigorous physical activity (MVPA) and sitting with risk of myeloid neoplasms (MN) or MN subtypes. We examined these associations in the Cancer Prevention Study-II Nutrition Cohort. Methods : Among 109,030 cancer-free participants (mean age 69.2, SD 6.1 years) in 1999, 409 were identified as having been diagnosed with a MN (n=155 acute myeloid leukemia [AML], n=154 myelodysplastic syndromes [MDS], n=100 other ML) through June 2013. Cox proportional hazards regression was used to calculate multivariable adjusted hazard ratios (HR) and 95% confidence intervals (CI) for associations of MVPA (MET-hours/week) and sitting (hours/day) with risk of all MN, myeloid leukemia only, MDS, and AML. Results: Compared to insufficient MVPA (>0-<7.5 metabolic equivalent [MET]-hours/week), the HR (95% CI) for meeting physical activity guidelines (7.5-<15 MET-hours/week MVPA) and risk of MN was 0.74 (95% CI, 0.56-0.98) and for doubling guidelines (15-<22.5 MET-hours/week) was 0.75 (0.53-1.07); however, there was no statistically significant association for higher MVPA (22.5+ MET-hours/week, HR=0.93, 0.73-1.20). Similarly, meeting/doubling guidelines was associated with lower risk of MDS (HR=0.57, 0.35-0.92/HR=0.51, 0.27-0.98), but there was no association for 22.5+ MET-hours/week (HR=0.93, 0.63-1.37). MVPA was not associated with risk of myeloid leukemia or AML. Sitting time was not associated with risk of any outcome. Conclusion : These results suggest that there may be a nonlinear association between MVPA and risk of MDS and possibly other MN. Impact : Further studies are needed to better understand the dose-response relationships between MVPA and risk of MDS, a highly fatal and understudied cancer.